| Description |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Aqvida |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Topotecan 4mg/4ml
|
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Sandoz |
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Himmel Pharma
|
Carboplatin 150mg/15ml |
| Product Type |
Product Size |
| Tablet |
20'S |
| Product Company |
| Mass Pharma |
Amlodipine 10mg
|
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Pfizer
|
Carboplatin 150mg/15ml
|
| Content | Paclitaxel is a taxoid chemotherapeutic agent used as first line and subsequently therapy for treatment of advanced carcinoma of the ovary and other cancers, including breast and lung cancer . PTX binds to microtublues instead of tubulin dimers and stabilizes microtubules by promoting the assembly of alpha and beta tubulin subunits,the building blocks of microtubules. | Topotecan is an antineoplastic agent used to treat ovarian cancer, small cell lung cancer, or cervical cancer.
| Oxaliplatin is a platinum based chemotherapy agent used to treat carcinoma of the colon or rectum or stage III colon cancer. | Carboplatin is an alkylating agent used to treat advanced ovarian cancer.Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
| Amlodipine, sold under the brand name Norvasc among others, is a calcium channel blocker medication used to treat high blood pressure and coronary artery disease. It is taken by mouth. | Carboplatin is a platinum-containing chemotherapy medicine, which belongs to the alkylating agents group of medicines. It is used to treat various cancers. It prevents growth of cancerous cells by damaging their DNA that aids in its proliferation.
|
Reviews
There are no reviews yet.